Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes
University of Calgary
The purpose of this study is to determine whether there is a difference in blood sugar
control (as measured by hemoglobin A1c (HA1c)), in children given twice daily insulin
injections incorporating a new long acting insulin analogue (detemir) compared to children
using their current three times a day insulin injections (with intermediate and rapid acting
Effect of Single Dose Intranasal Insulin On Cognitive Function
University of Massachusetts, Worcester
The purpose of the study is to find out how a small dose of insulin might affect memory, the
ability to concentrate, and improve your daily functioning in patients with schizophrenia and
schizoaffective disorders. Insulin is not being used to treat diabetes in this study. The
investigators propose a single dose, double-blinded, placebo-controlled trial of intranasal
insulin in 40 subjects with schizophrenia or schizoaffective disorder to examine insulin's
effect on cognition. The specific aims include:
1. Examine the effects of single doses of 40 IU intranasal insulin compared to placebo on
cognitive functioning, including attention and memory.
2. Examine whether single dose of intranasal insulin administration will raise serum
insulin level and decrease plasma glucose level
Insulin will be delivered through an air spray pump into your nose. The investigators will be
comparing one dose of insulin (40 International Units) with placebo, an inactive liquid.
Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)
Novo Nordisk A/S
This study is conducted in Europe. The aim of this observational study is to gain practical
experience with once-daily Levemir administration in type 2 diabetes patients who were
previously treated with Insulatard®, Humulin® N (NPH insulins) as basal insulin as part of
their ICT under normal clinical practice conditions in Hungary.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.